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Objective: To characterize large adrenal tumors (4 cm in diameter) and to identify features associated
with malignancy.
Patients and Methods: We investigated the clinical, biochemical, and imaging characteristics in a large
retrospective single-center cohort of patients with adrenal tumors of 4 cm or more in diameter during the
period of January 1, 2000, through December 31, 2014.
Results: Of 4085 patients with adrenal tumors, 705 (17%) had adrenal masses measuring 4 cm or more in
diameter; of these, 373 (53%) were women, with a median age of 59 years (range, 18-91 years) and median
tumor size of 5.2 cm (range, 4.0-24.4 cm). Underlying diagnoses were adrenocortical adenomas (n¼216
[31%]), pheochromocytomas (n¼158 [22%]), other benign adrenal tumors (n¼116 [16%]), adrenocortical
carcinomas (n¼88 [13%]), and other malignant tumors (n¼127 [18%]). Compared with benign tumors,
malignant tumors were less frequently diagnosed incidentally (45.5% vs 86.7%), were larger (7 cm [range,
4-24.4 cm] vs 5 cm [range, 4-20 cm]), and had higher unenhanced computed tomographic (CT) attenuation
(34.5 Hounsﬁeld units [HU] [range, 14.1-75.5 HU] vs 11.5 HU [range, 110 to 71.3 HU]; P<.001). On
multivariate analysis, older age at diagnosis, male sex, nonincidental mode of discovery, larger tumor size, and
higher unenhanced CT attenuation were all found to be statistically signiﬁcant predictors of malignancy.
Conclusion: The prevalence of malignancy in patients with adrenal tumors of 4 cm or more in diameter
was 31%. Older age, male sex, nonincidental mode of discovery, larger tumor size, and higher unen-
hanced CT attenuation were associated with an increased risk for malignancy. Clinical context should
guide management in patients with adrenal tumors of 4 cm or more in diameter.
ª 2017 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/) n Mayo Clin Proc Inn Qual Out 2018;2(1):30-39A drenal tumors are encountered inapproximately 5% of patients under-going cross-sectional imaging.1-3
Prevalence varies with age, ranging from less
than 0.5% in children4,5 to 10% in elderly
patients.6-8 Most adrenal tumors are discov-
ered incidentally on imaging performed for a
reason other than suspected adrenal disease;
however, at least 15% of patients with adrenal
tumors present with signs and symptoms of
adrenal hormonal excess.9 In every patient
with a newly discovered adrenal tumor, it is
essential to determine whether the adrenal
tumor is malignant and/or hormonally active.Mayo Clin Proc Inn Qual Out n March 20
rg n ª 2017 Mayo Foundation for Medical Education and Research
the CC BY-NC-NMost incidentally discovered adrenal tumors
are benign and nonfunctioning adrenocortical
adenomas (ACAs).9 Functional ACAs and
pheochromocytomas (PHEOs) are diagnosed in
11% to 15% and 4% to 10% of patients with
adrenal incidentalomas, respectively.9 Malignant
adrenal tumors (mainly adrenocortical
carcinomas [ACCs]) are diagnosed in up to 11%
of patients with adrenal incidentalomas.7,9
However, in patients with an active extraadrenal
malignancy, the likelihood of adrenal metastasis
varies widely between 2% and 71% depending
on the studied population, clinical presentation,
and underlying malignancy.10-1318;2(1):30-39 n https://doi.org/10.1016/j.mayocpiqo.2017.11.002
. Published by Elsevier Inc. This is an open access article under
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
LARGE ADRENAL TUMORSThe imaging characteristics of the adrenal
mass are helpful in determining the risk of
malignancy. The intracellular lipid content can
be approximated bymeasuringHounsﬁeld units
(HU) on unenhanced computed tomography
(CT) andwith the use of chemical shift magnetic
resonance imaging. Lipid-rich adrenal tumors
present with low unenhanced CT attenuation
and positive chemical shift on magnetic reso-
nance imaging and are consistent with ACAs.
Becausemost incidentally discovered adrenal tu-
mors are lipid-rich adenomas, guidelines9,14-16
recommend unenhanced CT as the initial imag-
ing study to excludemalignancy. An attenuation
threshold ofmore than 10HUhas a sensitivity of
93% to 100%, but a speciﬁcity of only 71% to
72% for detecting a malignancy.3 Thus, after
imaging, a clinically signiﬁcant proportion of
adrenal tumors remain indeterminate for
malignancy and require additional assessment.
Additional imaging modalities are often used
to further characterize adrenal masses, including
CT with contrast administration to assess for
absolute and relative contrast washout and
[18F]-ﬂuorodeoxyglucoseepositron emission
tomography integrated with CT to assess for
metabolic activity. However, evidence on the
diagnostic accuracy of these imaging modalities
is limited3; a recent publication by our group
demonstrated that [18F]-ﬂuorodeoxyglucosee
positron emission tomography integrated with
CT adrenal liver ratio of more than 1.8 diag-
nosed malignancy with a sensitivity of 87%
and speciﬁcity of 84%.17 When imaging is
inconclusive, various strategies may be consid-
ered including interval imaging to assess for tu-
mor growth, adrenalectomy, and, in selected
cases, adrenal biopsy.3,9,18,19
In patients with adrenal masses, the risk of
malignancy is directly proportional to the size of
the adrenal mass. Although several studies report
sensitivities of 80% to 93%, a tumor size
threshold of 4 cm is only 34% to 61% speciﬁc
for the diagnosis of a malignant adrenal
mass.7,20,21 The natural history of patients with
large adrenal tumors is not well studied and
most evidence originates from surgical
series.7,21,22 Several guidelines recommend
consideration of adrenalectomy for adrenal
masses greater than 4 to 6 cm.14-16 However,
more recent guidelines on adrenal incidentalomas
do not recommend an absolute size cutoff for
adrenalectomy, but suggest an individualizedMayo Clin Proc Inn Qual Out n March 2018;2(1):30-39 n https://do
www.mcpiqojournal.orgapproach with consideration of adrenalectomy
in large tumors.9 This equivocal recommendation
reﬂects the paucity of data on the management
and natural history of patients with large tumors.
An alternative explanation for the lack of a
consensus recommendation is that many vari-
ables tend tobe consideredwhendeciding on sur-
gery, including HU attenuation on unenhanced
CT, CT contrast washout behavior (if available),
growth or stability on follow-up imaging, patient
age, and comorbidities. Our objective was to
improve the understanding of the characteristics
of large adrenal tumors by retrospectively study-
ing a large cohort of patients with adrenal tumors
of 4 cm or more in diameter seen over a 15-year
period, in order to identify features associated
with malignancy.PATIENTS AND METHODS
This was a retrospective cohort study performed
at Mayo Clinic, Rochester, Minnesota, between
January 1, 2000, and December 31, 2014.
This study received approval from the Mayo
Clinic Institutional Review Board and included
only those patients who provided authorization
for research. All electronic medical records of pa-
tients with adrenal tumors diagnosed during the
study period were individually reviewed for in-
clusion criteria. Adult patients with adrenal tu-
mor size of at least 4 cm in largest diameter
were included in the study and detailed clinical,
imaging, biochemical, and histopathologic data
were collected. The functional status of adrenal
tumors was obtained through medical record re-
view. Overt hypercortisolism, primary hyperal-
dosteronism, and catecholamine excess were
diagnosed on the basis of most recent guide-
lines.23-25 Mild autonomous cortisol excess was
deﬁned as failure to suppress cortisol to less
than or equal to 1.8 mg/dL (to convert to
nmol/L, multiply by 27.59) after overnight dexa-
methasone administration (1 mg or 8 mg).9
We grouped all adrenal tumors into 5
main diagnostic categories, on the basis of
histology for patients who underwent adrenal-
ectomy and on the basis of cytology results if
adrenal biopsy was performed. For patients
in whom adrenalectomy or adrenal biopsy
was not performed, we used information on
clinical and radiological characteristics at
presentation and follow-up to determine the
ﬁnal diagnosis.i.org/10.1016/j.mayocpiqo.2017.11.002 31
TABLE 1. Demographic Characteristics, Clinical Presentation, and Management of Patients With Large Adrenal Tumorsa,b
Variable Total Pheochromocytoma ACA
Other benign
tumors ACC
Other
malignant
tumors
P value
(overall)
P value
(ACC vs other
malignancy)
No. (%) 705 158 (22) 216 (31) 116 (16) 88 (13) 127 (18)
Sex: female, No. (%) 373 (53) 84 (53) 134 (62) 55 (47) 56 (64) 44 (35) <.001c <.001c
Age at diagnosis (y),
median (range)
59 (18 to 91) 53 (18 to 87) 61 (25 to 91) 54 (20 to 84) 50 (19 to 85) 66 (18 to 88) <.001c <.001c
Mode of discovery, No. (%) <.001c <.001c
Incidental 472 (67) 86 (54) 184 (85) 104 (90) 37 (42) 61 (48)
Hormone excess 107 (15) 62 (39) 18 (8) 0 (0) 27 (31) 0 (0)
Cancer staging 61 (9) 3 (2) 6 (3) 3 (3) 5 (6) 48 (38)
Mass effect 51 (7) 6 (4) 6 (3) 9 (7) 18 (20) 12 (9)
B symptoms 14 (2) 1 (1) 2 (1) 0 (0) 1 (1) 6 (5)
Location of adrenal tumor, No. (%) <.001c <.001c
Right 297 (42) 76 (48) 81 (38) 53 (46) 43 (49) 45 (35)
Left 304 (43) 69 (44) 96 (44) 51 (44) 45 (51) 44 (35)
Bilateral 104 (15) 13 (8) 39 (18) 12 (10) 0 (0) 38 (30)
Adrenal mass diameter (cm),
median (range)
5.2 (4 to 24.4) 5.2 (4.0 to 20) 4.5 (4 to 17) 6.9 (4 to 20) 10.9 (4 to 24.4) 5.4 (4.0 to 18.6) <.001c <.001c
Unenhanced CT attenuation (HU),
median (range)
27 (110 to 76) 33 (18 to 60) 11 (64 to 71) 13 (110 to 55) 35 (18 to 76) 34 (14 to 56) <.001c .70
Available in No. (%) 360 (51) 63 (40) 138 (64) 70 (60) 41 (47) 48 (38)
Adrenal biopsy, No. (%) 103 (15) 13 (8) 15 (7) 10 (9) 19 (22) 46 (36) <.001c .02c
Adrenalectomy, No. (%) 457 (65) 155 (98) 118 (55) 57 (49) 77 (88) 50 (39) <.001c <.001c
aACA ¼ adrenocortical adenoma; ACC ¼ adrenocortical carcinoma; CT ¼ computed tomography; HU ¼ Hounsﬁeld unit.
bRange was deﬁned as minimum to maximum value.
cIndicates statistical signiﬁcance with P values <.05.
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TABLE 2. Accuracy of Tumor Size and Unenhanced CT Attenuation for the
Diagnosis of a Malignant Adrenal Massa,b
Tumor size/unenhanced CT
attenuation No. Sensitivity Speciﬁcity PPV NPV
Tumor size 6 cm 547 61% 71% 57% 74%
Unenhanced CT attenuation 10 HU 297 100% 46% 44% 100%
Unenhanced CT attenuation 20 HU 297 98% 64% 54% 98.5%
aCT ¼ computed tomography; HU ¼ Hounsﬁeld units; NPV ¼ negative predictive value; PPV ¼
positive predictive value.
bPheochromocytomas were excluded from this analysis.
TABLE 3. Clinical Presentation of Patients With Large Adrenal Tumors Based
on Surgical or Conservative Managementa,b
Variable Adrenalectomy
Conservative
management P valuec
No. (%) 457 (65) 248 (35)
Sex: female, No. (%) 26 (57) 111 (45) .001
Age at diagnosis (y), median (range) 55 (18-87) 64 (18-91) <.001
Mode of discovery, No. (%) <.001
Incidental 290 (63) 182 (73)
Hormone excess 95 (21) 12 (5)
Cancer staging 30 (7) 31 (13)
Otherd 42 (9) 23 (9)
Evaluated by endocrinologist: yes, No. (%) 392 (86) 170 (69) <.001
Diagnosis, No. (%) <.001
Adenoma 118 (55) 98 (45)
Pheochromocytoma 155 (98) 3 (2)
Other malignant 50 (39) 77 (61)
Other benign 57 (49) 59 (51)
ACC 77 (88) 11 (12)
Adrenal mass diameter (cm), median (range) 5.5 (4-24.4) 5 (4-15.3) <.001
Bilateral, No. (%) 44 (10) 60 (24) <.001
aACC ¼ adrenocortical carcinoma.
bRange was deﬁned as minimum to maximum value.
cIndicates statistical signiﬁcance.
dOther: mass effect and B symptoms.
LARGE ADRENAL TUMORSRadiological Assessment
All radiology reports of cross-sectional imag-
ing were reviewed. In addition, an experienced
radiologist personally reviewed unenhanced
CT images. A CT linear measurement tool
was used to determine the largest diameter
of the adrenal mass in the axial plane. To
determine the CT attenuation values, an oval
region-of-interest cursor was used. The region
of interest covered two-thirds to three-quarters
of the adrenal mass. The mass boundary, cal-
ciﬁcations, and areas of necrosis were avoided.
Statistical Analyses
A descriptive summary analysis of patients’
baseline characteristics was performed using
JMP, version 10.0.0 (SAS Institute). The ﬁnd-
ings are presented as frequencies (percentages)
for the categorical variables and median
(ranges) for the continuous variables. Differ-
ences between categorical variables were
assessed using the Pearson c2 test. Differences
between continuous variables were assessed
using the Wilcoxon/Kruskal-Wallis test. Logis-
tic regression was used to differentiate malig-
nancy groups on the basis of predeﬁned
predictors. A P value of less than .05 was
considered statistically signiﬁcant.
RESULTS
Patients
During the 15-year study period, 4085 pa-
tients with adrenal tumors were evaluated at
Mayo Clinic in Rochester, MN; 705 (17%) pa-
tients had a maximum adrenal tumor diameter
of 4 cm or more (median size, 5.2 cm; range,
4.0-24.4 cm). Patients were diagnosed with an
adrenal tumor at a median age of 59 years
(range, 18-91 years), 373 (53%) patients
were women, and the vast majority were white
(n¼631 [90%]) (Table 1).
Overall, 215 (31.0%) patients were found
to have a malignant adrenal mass (13.0% ACC
and 18.0% other malignant tumors). Adreno-
cortical adenoma was diagnosed in 216
(30.6%) patients, PHEO in 158 (22.4%),
and other benign adrenal tumors (myeloli-
poma, cyst, ganglioneuroma) in 116 (16.4%)
patients. Patients with ACA and malignant tu-
mors other than ACC were diagnosed at an
older age than were patients with ACC, other
benign tumors, and PHEO (P<.001)Mayo Clin Proc Inn Qual Out n March 2018;2(1):30-39 n https://do
www.mcpiqojournal.org(Table 1). Adrenocortical adenoma, ACC,
and PHEO were more commonly diagnosed
in women, whereas other benign or malignant
tumors were more frequently diagnosed in
men. No patient with ACC had bilateral adre-
nal disease, but 30% of patients with other
malignant tumors presented with bilateral dis-
ease (Table 1). Adrenocortical carcinomas had
the largest median tumor size (10.9 cm
[range, 4.0-24.4 cm]), followed by benign tu-
mors other than ACA (6.9 cm [4.0-20.0 cm]),
malignant tumors other than ACC (5.4 cm
[4.0-18.6 cm]), PHEO (5.2 cm [4.0-20.0
cm]), and ACA (4.5 cm [4.0-17.0 cm])
(P<.001). Compared with benign tumors,
malignant tumors were less frequentlyi.org/10.1016/j.mayocpiqo.2017.11.002 33
TABLE 4. Demographic Characteristics and Clinical, Imaging, and Biochemical Presentation of Patients With Large Adenomasa,b
Variable All adenomas Adrenalectomy
Conservative
management
P value
(adrenalectomy vs
conservative)
No. (%) 216 118 (55) 98 (45)
Sex: female, No. (%) 134 (62) 78 (66) 56 (57) .18
Age at diagnosis (y), median (range) 61 (25 to 91) 58 (25 to 87) 63 (28 to 91) .003c
Mode of discovery, No. (%) .22
Incidental 184 (85) 102 (86) 82 (84)
Hormone excess 18 (8) 12 (10) 6 (6)
Otherd 14 (7) 4 (4) 10 (10)
Evaluated by endocrinologist: yes, No. (%) 181 (84) 103 (87) 78 (80) .13
Location, No. (%) .08
Right 81 (38) 48 (40) 33 (34)
Left 96 (44) 55 (47) 41 (42)
Bilateral 39 (18) 15 (13) 24 (24)
Adrenal mass diameter (cm),
median (range)
4.5 (4 to 17) 4.8 (4 to 17) 4.4 (4 to 11.8) .04c
Unenhanced CT attenuation (HU),
median (range)
Available for 138 patients:
10.5 (63.8 to 71.3)
Available for 69 patients:
14 (64 to 71)
Available for 69 patients:
9 (19 to 60)
.06
Unenhanced CT attenuation
(HU category), No. (%)
Available for 138 patients: Available for 69 patients: Available for 69 patients: .04c
10 HU 68 (49) 28 (41) 40 (58)
>10 HU 70 (51) 41 (59) 29 (42)
Hormonal excess, No. (%) .002c
No hormonal excess 111 (51) 46 (39) 65 (66)
Overt cortisol excess 11 (5) 9 (7.6) 2 (2)
Mild cortisol excess 88 (41) 59 (50) 29 (30)
Hyperaldosteronism 5 (2) 3 (2.5) 2 (2)
Androgen excess 1 (0.5) 1 (0.9) 0 (0)
aCT ¼ computed tomography; HU ¼ Hounsﬁeld units.
bRange was deﬁned as minimum to maximum value.
cIndicates statistical signiﬁcance with P values <.05.
dOther: cancer staging, mass effect, and B symptoms.
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34diagnosed incidentally (45.5% vs 86.7%),
were larger (7 cm [range, 4-24.4 cm] vs 5
cm [range, 4-20 cm]), and had higher unen-
hanced CT attenuation (34.5 HU [range,
14.1 to 75.5 HU] vs 11.5 HU [range, 110
to 71.3 HU]; P<.001). Unenhanced CT atten-
uation (>10 HU) had 100% sensitivity but
only 46% speciﬁcity for detecting malignancy.
An unenhanced CT attenuation cutoff of more
than 20 HU had similar sensitivity but better
speciﬁcity, albeit still low at 64% (Table 2).
Mode of Adrenal Mass Discovery
Regardless of tumor type, most adrenal masses
were diagnosed incidentally (n¼472 [67%])
(Table 1). Cross-sectional imaging obtained
because of clinical and/or biochemical presen-
tation with adrenal hormonal excess was theMayo Clin Proc Inn Qual Out n March 20second most common mode of discovery for
PHEO (39%), ACC (31%), and ACA (8%).
Cancer staging/surveillance imaging was the
second most frequent mode of discovery
(38%) for malignant tumors other than ACC
(Table 1).
Patients with incidentally discovered
adrenal masses had lower rates of malignancy
(21% vs 50%; P<.001), were older at the
time of diagnosis (median, 60 years [range,
19-88 years] vs 54 years [range, 18-91 years];
P<.001), and presented with smaller tumors
than did patients whose tumors were discov-
ered because of symptoms or during cancer
staging (median, 5.0 cm [range, 4.0-20.0 cm]
vs 6.0 cm [range, 4.0-24.4 cm]; P<.001)
(Supplemental Table 1, available online at
http://mcpiqojournal.org/).18;2(1):30-39 n https://doi.org/10.1016/j.mayocpiqo.2017.11.002
www.mcpiqojournal.org
TABLE 5. Multivariate AnalysisdPredictors of a Malignant Adrenal Massa
Any malignant mass
Variable
All patientsb (n¼547)
Only for patients with unenhanced
HU measurements availableb
(n¼297)
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Sex (male vs female) 1.57 (1.04-2.37) .03c 1.45 (0.72-2.95) .29
Age at diagnosis (each decade increase) 1.2 (1.04-1.37) .01c 1.08 (0.86-1.4) .49
Mode of discovery (nonincidental vs incidental) 6.99 (4.5-10.99) <.001c 5.92 (2.7-13.4) <.001c
Adrenal mass size (each 1-cm increase) 1.2 (1.14-1.3) <.001c 1.3 (1.17-1.48) <.001c
Unenhanced CT attenuation (each 1-HU increase) 1.08 (1.06-1.1) <.001c
Other malignancy
Variable
All patientsb (n¼547)
Only for patients with available
work-up for adrenal glucocorticoid
productionb (n¼393)
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Sex (male vs female) 2.4 (1.5-3.9) .002c 1.8 (0.95-3.4) .07
Age at diagnosis (each decade increase) 1.45 (1.2-1.7) <.001c 1.6 (1.3-2.1) <.001c
Mode of discovery (nonincidental vs incidental) 7.8 (4.7-13) <.001c 5.5 (2.8-11) <.001c
Adrenal mass size (each 1-cm increase) 1.1 (0.98-1.15) .17 0.9 (0.8-1) .05c
Hypercortisolism (vs normal cortisol production) 0.2 (0.1-0.4) <.001c
ACC
Variable
All patientsb (n¼547)
Only for patients with available
work-up for adrenal glucocorticoid
productionb (n¼393)
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Sex (male vs female) 0.53 (0.29-0.95) .03c 0.79 (0.37-1.6) .52
Age at diagnosis (each decade increase) 0.83 (0.69-0.99) .04c 0.83 (0.67-1.02) .08c
Mode of discovery (nonincidental vs incidental) 2.48 (1.4-4.4) .002c 2.9 (1.4-5.9) .003c
Adrenal mass size (each 1-cm increase) 1.36 (1.27-1.47) <.001c 1.5 (1.37-1.68) <.001c
Hypercortisolism (vs normal cortisol production) 3.5 (1.7-7.6) <.001c
aCT ¼ computed tomography; HU ¼ Hounsﬁeld units.
bPheochromocytomas were excluded from this analysis.
cIndicates statistical signiﬁcance with P values <.05.
LARGE ADRENAL TUMORSAdrenalectomy in Patients With Adrenal
Tumors
Adrenalectomy was performed in 457 (65%)
patients with large adrenal tumors. Adrenal-
ectomy was performed in 88% of patients
with ACC and 98% of patients with
PHEO. The remainder of patients with
ACC and PHEO chose nonsurgical or pallia-
tive care approaches because of poor func-
tional status or incurable metastatic disease
(Table 3). The rate of adrenalectomy was
higher in patients with tumors of more
than 6 cm in diameter, mainly due to a
higher prevalence of ACCs and largeMayo Clin Proc Inn Qual Out n March 2018;2(1):30-39 n https://do
www.mcpiqojournal.orgmyelolipomas (Supplemental Table 2, avail-
able online at http://mcpiqojournal.org/).
Just over half (55%) of patients with large
adenomas were treated surgically (Table 4). In
contrast to patients with large adenomas who
were treated conservatively, patients with
adenomas treated with adrenalectomy were
younger (median, 58 years [range, 25-87 years]
vs 63 years [range, 28-91 years]; P¼.003), had
slightly larger adrenal tumors (median, 4.8 cm
[range, 4.0-17.0 cm] vs 4.4 cm [range, 4.0-11.8
cm]; P¼.04), were more frequently diagnosed
with hormonal excess (61% vs 34%; P¼.002),
and had a higher prevalence of indeterminatei.org/10.1016/j.mayocpiqo.2017.11.002 35
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36imaging characteristics (tumor CT attenuation
>10 HU in 59% vs 42% of patients; P¼.04)
(Table 4).
Features Associated With Malignant Adrenal
Masses
To identify characteristics associated with malig-
nancy, we performed a multivariate analysis of a
cohort of patients after excluding PHEOs
(n¼547). Male sex (odds ratio [OR], 1.57 [95%
CI, 1.04-2.37]), older age at diagnosis (OR, 1.2
for each decade increase [95% CI, 1.04-1.37]),
nonincidental mode of discovery (OR, 6.99
[95% CI, 4.5-10.99]), and tumor size (OR, 1.2
for each 1-cm increase in size >4 cm [95% CI,
1.14-1.3]) were signiﬁcant predictors of malig-
nancy. Multivariate analysis of the subgroup of
patients with available measurements of tumor
attenuation on unenhancedCT (n¼297) revealed
that tumor CT attenuation (OR, 1.08 for each 1-
HU increase [95% CI, 1.06-1.1]), tumor size
(OR, 1.3 for each 1-cm increase in tumor size
>4 cm [95% CI, 1.17-1.48]), and nonincidental
mode of discovery (OR, 5.92 [95% CI, 2.7-
13.4]) were statistically signiﬁcant predictors of
malignancy (Table 5).
Because patients with ACC present
differently than patients with other malignant
adrenal tumors, we performed a multivariate
analysis of features predictive of ACC vs non-
ACC. Female sex (OR, 0.53 for male vs female
[0.29-0.95]), younger age of diagnosis (OR,
0.83 for each decade increase [0.69-0.99]),
nonincidental mode of discovery (OR, 2.48
[1.4-4.4]), and size (OR, 1.36 for each 1-cm in-
crease [1.27-1.47]) were signiﬁcant predictors
of ACC. A subgroup analysis of patients with
available work-up for hypercortisolism
(n¼393) revealed that the presence of cortisol
excess was a signiﬁcant predictor of ACC (OR,
3.5 [1.7-7.6]; P<.001). In contrast, for patients
with malignant tumors other than ACC, male
sex (OR, 2.4 [1.5-3.9]) and older age at the
time of diagnosis (OR, 1.45 [1.2-1.7]) were sig-
niﬁcant predictors of malignancy, whereas size
was not (P¼.17), likely reﬂecting earlier adrenal
mass detection due to (P<.001) cancer staging/
surveillance imaging (Table 5).
DISCUSSION
We found that patients with adrenal tumors of at
least 4 cm in diameter represent a heterogeneous
group with an overall malignancy rate of 31%.Mayo Clin Proc Inn Qual Out n March 20We found that older age at the time of discovery
of an adrenal mass, male sex, nonincidental
mode of discovery, larger tumor size, and inde-
terminate imaging characteristics are predictors
of a malignant adrenal mass. However, there
are important differences in presentation and
risk factors for ACC vs other malignant tumors,
most notably sex (64% vs 35% women), age at
diagnosis (median of 50 vs 66 years), and the
presence of bilateral adrenal tumors (0% vs
30%). Although the absence of adrenal hormon-
al excess does not exclude ACC, the presence of
hypercortisolism is strongly indicative of ACC
over other malignant adrenal masses. Active
extraadrenal malignancy is an important factor
because more than a third of malignant adrenal
lesions other than ACC were metastases discov-
ered during cancer staging imaging for an extra-
adrenal primary malignancy.
Larger tumor size has previously been
reported to be associated with malignancy. In a
multicenter survey of 1096 patients with inciden-
tally discovered adrenal tumors, a tumor size
threshold of at least 4 cm distinguished ACC
from benign adrenal tumors with a sensitivity of
93% but a speciﬁcity of only 42%.7 In concor-
dance with our ﬁndings, using a higher threshold
of at least 6 cm resulted in a higher speciﬁcity
(73%) but a lower sensitivity (74%).7 The reason
for suboptimal accuracy of size alone as a predic-
tor of malignancy is the high rate of ACAs and
other benign tumors among adrenal tumors of
at least 4 cm in diameter (false-positives). Further-
more, adrenal metastases are usually detected
during imaging for cancer staging, before clini-
cally signiﬁcant growth occurs (false-negatives).
Of all adrenal tumors evaluated during the
study period, we found that the prevalence of
adrenal tumors of at least 4 cm in diameter
was 17%. In a multicenter Italian study of ad-
renal incidentalomas published in 2000, at
least one-third of patients had adrenal tumors
of at least 4 cm in diameter.20 Higher fre-
quency of imaging and improved quality of
cross-sectional imaging could explain the
signiﬁcantly lower prevalence in our study
and the even lower frequencies reported in
another study.2
In our study, we found that all malignant
adrenal tumors demonstrated an unenhanced
CT attenuation of more than 10 HU (100%
sensitivity). However, approximately only
half of benign adrenal tumors had tumor CT18;2(1):30-39 n https://doi.org/10.1016/j.mayocpiqo.2017.11.002
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ﬁcity). An unenhanced CT attenuation
threshold of at least 20 HU had similar sensi-
tivity of 98% but slightly higher speciﬁcity
(64%) for malignancy. In a recent systematic
review on the accuracy of imaging characteris-
tics for the diagnosis of a malignant adrenal
mass, an unenhanced CT attenuation
threshold of at least 10 HU demonstrated a
high sensitivity but a low speciﬁcity.3 A study
on surgical series of consecutive patients with
adrenal tumors of any size demonstrated
similar ﬁndings of noncontrast CT attenuation
cutoffs of both 10 and 20 HU in the diagnosis
of “nonadenomas.”21
Pheochromocytomas were diagnosed in
22% of our cohort patients, with approxi-
mately half being discovered incidentally
(54%). Thus, it is essential to biochemically
exclude PHEO, especially in an adrenal mass
with indeterminate imaging characteristics.
The prevalence of PHEO in patients with inci-
dentally discovered adrenal tumors of any size
was previously reported to be 4.2%.7 Other
data derived from surgical series are difﬁcult
to compare with our cohort of patients, espe-
cially considering the differences in tumor size
cutoff.7,20 In our cohort, all 158 PHEOs with
available unenhanced CT images demon-
strated attenuation of more than 10 HU.
This ﬁnding is consistent with another
study,21 in which the mean unenhanced HU
was 38.68.2 and all 63 PHEOs demon-
strated unenhanced CT attenuation of more
than 10 HU. On the basis of our ﬁndings,
we conclude that when a homogeneous adre-
nal mass of more than 4 cm in diameter has
an unenhanced CT attenuation of less than
10 HU, biochemical testing for PHEO is not
needed.
Adrenocortical adenomas were found in
31% of our cohort patients. Most patients
with ACAs were discovered incidentally
(85%); however, half of the patients demon-
strated biochemical evidence of adrenal hor-
monal excess. In patients with functioning
adrenal tumors, overt and mild cortisol excess
were most common, whereas primary aldoste-
ronism was documented in only 5 patients.
Almost half of the patients with nonfunc-
tioning adenomas were treated surgically. In
concordance with our ﬁndings, a surgical se-
ries9 of patients with adrenal tumors reportedMayo Clin Proc Inn Qual Out n March 2018;2(1):30-39 n https://do
www.mcpiqojournal.orgthat 52% to 75% of patients undergoing adre-
nalectomy were diagnosed with a nonfunc-
tioning adrenal tumor. Therefore, it is likely
that many patients undergo an adrenalectomy
unnecessarily. The decision to proceed with
adrenalectomy likely reﬂects the uncertainty
of diagnostic evaluation due to suboptimal
accuracy of available imaging tests and the
concern for malignancy due to size and/or
tumor attenuation. A new diagnostic modality
expected to be introduced into clinical practice
soon is urine steroid metabolomics; this test
has demonstrated 90% sensitivity and speci-
ﬁcity in a proof-of-concept study,26,27 with
prospective validation underway.
Strengths and Limitations
This is a large study addressing a population of
patients with large adrenal tumors, which to
date has not been well characterized. The retro-
spective nature meant that not all variables were
available for all patients, which also reﬂects the
heterogeneity in the management of patients
with large adrenal tumors. Enrollment of all
consecutive patients with large adrenal tumors
over a 15-year period allowed for a thorough
study of patients who were managed medically.
Although this is a single-institution referral cen-
ter and our study may overestimate the preva-
lence of malignant adrenal tumors, it is
reﬂective of the current standard of care to refer
such patients to a center with adrenal expertise.
In addition, a subgroup analysis of incidentally
discovered large adrenal tumors is likely gener-
alizable to other institutions.
Clinical Implications
It is important to note that in a third of the
patients with malignant adrenal tumors, the
diagnostic evaluation and management differed
on the basis of etiology. We recommend that
the management of patients with large adrenal
tumors should be individualized to the patient’s
circumstances and presentation, taking into ac-
count patient age, sex,mode of discovery, imag-
ing phenotype including unenhanced CT
tumor attenuation, rate of tumor growth and
size, hormonal activity, and comorbidities. An
active or previously diagnosed extraadrenal
malignancy should raise the suspicion for
metastases.
In our cohort of patientswith large adrenal tu-
mors, we have observed that all ACCs, malignanti.org/10.1016/j.mayocpiqo.2017.11.002 37
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38tumors other than ACCs, and PHEOs of at least 4
cm demonstrated unenhanced CT attenuation of
more than 10 HU. Therefore, in homogeneous
adrenal tumors with unenhanced CT attenuation
of less than 10 HU, additional diagnostic tests to
establish the diagnosis of malignancy or PHEO
are unnecessary given the low likelihood of their
presence. In contrast, when unenhanced CT
attenuation is more than 10 HU in large adrenal
tumors, further diagnostic tests and adrenalec-
tomy need to be considered.CONCLUSION
Large adrenal tumors are most frequently diag-
nosed incidentally and encompass a heteroge-
neous group. Tumor size alone is not a reliable
determinant of malignancy. The overall preva-
lence of malignancy in patients with adrenal
tumors of at least 4 cm in diameter was
31%. Risk of malignancy was associated with
age at diagnosis, male sex, nonincidental
mode of discovery, larger tumor size, and
indeterminate imaging characteristics. All
ACCs, PHEOs, and malignant adrenal tumors
other than ACC demonstrated unenhanced CT
attenuation of more than 10 HU, which sup-
ports the concept that malignancy and
PHEO can be excluded with certainty in pa-
tients with adrenal tumors with unenhanced
CT attenuation of less than 10 HU. We suggest
that clinical context, hormonal assessment,
and image phenotype can together determine
the need for adrenalectomy in patients with
adrenal tumors of at least 4 cm in diameter.
Patients with large adrenal tumors should be
managed by an expert multidisciplinary team
that includes endocrinologists, radiologists,
and adrenal surgeons.Abbreviations and Acronyms: ACA = adrenocortical ad-
enoma; ACC = adrenocortical carcinoma; CT = computed
tomography; HU = Hounsﬁeld units; OR = odds ratio; PHEO
= pheochromocytoma
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